Literature DB >> 23128601

Interactions of oxaliplatin with the cytoplasmic thiol containing ligand glutathione.

Tamer Shoeib1, Barry L Sharp.   

Abstract

The complexation of the Pt-based anti-cancer drug oxaliplatin (OxPt) with biological ligands other than DNA is believed to be a major cellular sink for the drug reducing its therapeutic effect and acting as a potential cause of toxicity. In this paper, linear ion trap electrospray ionization mass spectrometry was employed to study the interaction of oxaliplatin with the cytoplasmic thiol containing tripeptide ligand γ-l-glutamyl-l-cysteinyl-glycine (GSH) this being the most abundant low-molecular-weight thiol containing molecule in human cells. Evidence of protonated dimers and multimers of oxaliplatin, protonated multimers of glutathione as well as several different combinations of these protonated species is presented. Most species observed were unambiguously assigned and compared to their theoretical isotopic patterns. Fragmentation of the collisionally-activated protonated complex of glutathione with oxaliplatin [GSH + OxPt + H](+) resulted in the formation of several species. No experimental evidence for [GSH + H](+) formation from the [OxPt + GSH + H](+) precursor was observed. Density functional calculations at B3LYP/LANL2DZ were used to obtain structural information and relative free energies of different isomers of the observed precursor [OxPt + GSH + H](+) both in the gas phase and in solution as well as to probe its fragmentation, highlighting mechanisms that account for all the experimental results. Data are presented to show several binding modes between electron rich sites such as S, N, O centers of GSH and the Pt metal of oxaliplatin. Calculations were also employed to obtain proton affinities and free energies of key reactions. The proton affinities of GSH and OxPt at 298 K were calculated to be 255.3 and 233.5 kcal mol(-1) respectively. The enthalpy and free energy, based on the most thermodynamically favored conformers of the reactants and products, for the addition reaction [Pt(dach)](2+) + [GSH - H](-) → [GSH - H + Pt(dach)](+) (where dach represents diaminocyclohexane) in the gas phase at 298 K were determined to be -311.3 and -290.2 kcal mol(-1) respectively. Similarly, the enthalpy of the gas phase reaction [Pt(dach)](2+) + GSH → [GSH + Pt(dach)](2+) at 298 K was determined to be -169.2 kcal mol(-1).

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23128601     DOI: 10.1039/c2mt20127e

Source DB:  PubMed          Journal:  Metallomics        ISSN: 1756-5901            Impact factor:   4.526


  5 in total

1.  Bismuth(III) α-hydroxy carboxylates: highly selective toxicity of glycolates towards Leishmania major.

Authors:  Allan Loh; Yih Ching Ong; Victoria L Blair; Lukasz Kedzierski; Philip C Andrews
Journal:  J Biol Inorg Chem       Date:  2015-09-28       Impact factor: 3.358

2.  Oxaliplatin Modulates the Characteristics of Voltage-Gated Calcium Channels and Action Potentials in Small Dorsal Root Ganglion Neurons of Rats.

Authors:  Linda-Isabell Schmitt; Markus Leo; Christoph Kleinschnitz; Tim Hagenacker
Journal:  Mol Neurobiol       Date:  2018-03-30       Impact factor: 5.590

3.  The clinical analysis of acute pancreatitis in colorectal cancer patients undergoing chemotherapy after operation.

Authors:  Yanlei Ji; Zhen Han; Limei Shao; Yunling Li; Long Zhao; Yuehuan Zhao
Journal:  Onco Targets Ther       Date:  2015-09-11       Impact factor: 4.147

4.  Rapid screening of photoactivatable metallodrugs: photonic crystal fibre microflow reactor coupled to ESI mass spectrometry.

Authors:  Ruth J McQuitty; Sarah Unterkofler; Tijmen G Euser; Philip St J Russell; Peter J Sadler
Journal:  RSC Adv       Date:  2017-07-26       Impact factor: 3.361

5.  Mitochondrial Dynamics Mediated by DRP1 and MFN2 Contributes to Cisplatin Chemoresistance in Human Ovarian Cancer SKOV3 cells.

Authors:  Guang-Ping Zou; Chun-Xia Yu; Sheng-Lan Shi; Qiu-Gen Li; Xiao-Hua Wang; Xin-Hui Qu; Zhang-Jian Yang; Wei-Rong Yao; Dan-Dan Yan; Li-Ping Jiang; Yu-Ying Wan; Xiao-Jian Han
Journal:  J Cancer       Date:  2021-10-28       Impact factor: 4.207

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.